FIGURE

Figure 10

ID

ZDB-FIG-240229-157

Publication

Chen et al., 2024 - Lactylation-driven FTO targets CDK2 to aggravate microvascular anomalies in diabetic retinopathy

Other Figures

All Figure Page

Back to All Figure Page

Figure 10

FB23-2 suppresses demethylation activity of FTO to inhibit diabetes induced endothelial phenotypes in vitro.

(A) m⁶A dot blot assay of global m⁶A abundance in HUVECs treated with or without FB23-2 (2 µM) using 800 or 400 ng total RNAs. MB staining is used as a loading control. n = 3 per group. (B) Immunoblotting of FTO in HUVECs treated with or without FB23-2. GAPDH is used as an internal control. n = 3 per group. (C) EdU assay on HUVECs treated with NG, HG, as well as HG and FB23-2. n = 3 per group. Scale bar: 60 µm. (D) Scratch test on HUVECs receiving indicated treatments. n = 3 per group. Scale bar: 100 µm. (E) Tube formation analyses on HUVECs treated with NG, HG, as well as HG and FB23-2. n = 3 per group. Scale bar: 100 µm. Data information: Data represent different numbers (n) of biological replicates. Data are shown as mean ± SEM. Two-tailed Student’s t test is used in (A, B). One-way ANOVA followed by Bonferroni’s test is used in (C–E). NS: not significant (p > 0.05); *p < 0.05; **p < 0.01; and ***p < 0.001. Source data are available online for this figure.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ EMBO Mol. Med.